Initially awarded $50 million, he now must choose between a reduced award of $1.6 million, or a new trial.
Vioxx plaintiff faces a choice
More in Uncategorized
Past Week
-
Medicine is not apolitical: Your vote dictates your ability to practice medicine
-
Navigating organizational dysfunction: lessons from Boeing
-
Too many older adults are taking risky sedative medications
-
The Supreme Court must consider science, not pseudo-science, in public health rulings
-
Talk to your patients about money
-
AI’s role in simplifying communication [PODCAST]
-
Past 6 Months
-
Medicine is not apolitical: Your vote dictates your ability to practice medicine
-
The abuser’s playbook: the weaponization of mental health
-
Real pain deserves real treatment
-
From fear of loneliness to embracing solitude
-
The spiritual crisis of the employed physician
-
Wendy Williams’s battle with health and the fragility of success
-
Recent Posts
-
AI’s role in simplifying communication [PODCAST]
-
Practicing patience with patients
-
GLP-1 medications like Wegovy are effective metabolic health tools for teens with insulin resistance
-
Embracing imperfection: strategies for growth and self-compassion [PODCAST]
-
Post-delivery complications: a glimpse into obstetric care
-
Elite access vs. public scrutiny: Medication disparities exposed
-
Subscribe to KevinMD and never miss a story!
Get free updates delivered free to your inbox.
